Delonix Bioworks Enters Clinical Stage with Dual Clearance for Next-Generation Meningitis B Vaccine

SHANGHAI, CHINA – February 06, 2026 – Delonix Bioworks has officially transitioned to a clinical-stage company, announcing it has received dual regulatory clearance to begin human trials for its promising Group B meningococcal (MenB) vaccine candidate, DX-104. The Shanghai-based biotechnology firm secured Investigational New Drug (IND) clearance from China's National Medical Products Administration (NMPA) and, in parallel, completed Clinical Trial Notification (CTN) procedures and received ethics approval in Australia.

These critical approvals pave the way for Delonix to initiate Phase I clinical trials in the near future across both countries. The studies will evaluate the safety and immunogenicity of DX-104, a vaccine designed to combat a life-threatening bacterial infection that disproportionately affects infants and young adults. This milestone positions Delonix as a serious contender in the global fight against invasive meningococcal disease (IMD) and validates its innovative vaccine development platform.

A New Challenger in a Billion-Dollar Market

The global market for MenB vaccines is both substantial and highly concentrated, dominated by pharmaceutical giants GSK and Pfizer. GSK's Bexsero®, a market leader, generated sales of approximately $1.58 billion in 2025, underscoring the significant commercial and clinical value placed on preventing this dangerous disease. Pfizer’s Trumenba® also holds a significant market share.

Despite the success of these established vaccines, significant gaps remain. Public health officials and medical experts point to challenges in global access and incomplete coverage against the diverse and evolving strains of serogroup B meningococcus, which is responsible for about half of all IMD cases worldwide. This creates a critical opportunity for a new generation of vaccines that can offer broader protection, improved tolerability, and a more scalable manufacturing process to ensure equitable global supply.

DX-104 is engineered to address these very shortcomings. By leveraging a novel technological platform, Delonix aims to deliver a best-in-class vaccine that could potentially expand strain coverage and be produced more cost-effectively, thereby improving accessibility for vulnerable populations in regions where current vaccines are unavailable or unaffordable.

The Science Behind DX-104: The OMV Plus® Advantage

At the core of Delonix Bioworks' innovation is its proprietary OMV Plus® platform. This technology utilizes precisely engineered outer membrane vesicles (OMVs)—particles naturally shed from the surface of bacteria—to serve as the vaccine's base. Unlike traditional vaccine approaches, Delonix genetically engineers the source bacteria to optimize these OMVs, turning them into potent vehicles for antigen presentation.

A key differentiator of the OMV Plus® platform is that the resulting vesicles possess intrinsic adjuvant properties. Adjuvants are substances added to most vaccines to boost the body's immune response. By designing a vaccine that does not require external adjuvants, Delonix may be able to reduce the potential for injection site reactions and other side effects, a significant advantage in pediatric and adolescent vaccination schedules. This also simplifies the formulation and manufacturing process, contributing to cost-effectiveness and consistency.

Preclinical studies have already shown significant promise. According to the company, DX-104 induced robust and functional serum bactericidal antibody (SBA) responses, the gold standard for measuring protection against meningococcal disease. Furthermore, Delonix reports that it has already achieved commercial-scale production of DX-104 with high batch-to-batch consistency, a crucial step in de-risking the path to market and ensuring a reliable global supply chain can be established if the vaccine proves successful in clinical trials.

A Global Strategy Bridging East and West

The dual regulatory clearances from China and Australia are not merely a procedural step; they represent a sophisticated global development strategy. By pursuing parallel pathways in two distinct regulatory environments, Delonix is demonstrating its capability to operate on an international stage and is accelerating its clinical timeline. Securing IND clearance from China's NMPA is particularly noteworthy, highlighting the country's rising influence and increasingly rigorous standards in biopharmaceutical research and development.

Simultaneously satisfying Australia's Therapeutic Goods Administration (TGA) notification scheme and Human Research Ethics Committee (HREC) requirements underscores the robustness of Delonix's preclinical data and trial protocols, which must adhere to stringent international GCP (Good Clinical Practice) standards. This dual-hemisphere approach could facilitate broader and more rapid patient recruitment and generate data applicable to a diverse global population.

"The dual regulatory clearances in China and Australia mark a transformative milestone for Delonix Bioworks as we transition into a clinical-stage company," said Qiubin Lin, CEO and Founder of Delonix Bioworks, in a statement. "This is a crucial step in our global strategy to deploy engineered bacterial vaccines that are designed to be highly immunogenic, well-tolerated, and scalable. We are committed to addressing the urgent unmet medical needs of patients worldwide."

The Human Cost of Meningitis and the Path Forward

Invasive meningococcal disease remains a feared public health threat. It can progress with shocking speed, leading to meningitis (inflammation of the brain and spinal cord lining) and septicemia (blood poisoning). Even with treatment, IMD has a high fatality rate, and survivors are often left with devastating long-term disabilities, including brain damage, hearing loss, or limb amputations. Infants, adolescents, and young adults in group settings like college dormitories are at the highest risk.

With regulatory hurdles cleared, the focus now shifts to the upcoming Phase I clinical trials. These initial human studies are designed primarily to assess the safety and tolerability of DX-104 in healthy volunteers. Researchers will also collect initial data on the vaccine's immunogenicity, measuring the antibody response it generates. The successful execution of these trials in China and Australia will be the first concrete test of the OMV Plus® platform in humans and a critical step toward potentially protecting millions from this devastating disease.

Delonix is also advancing a pipeline of other vaccine candidates using its platform, targeting challenging pathogens such as pertussis, gonorrhoeae, and K. pneumoniae. The progress of DX-104 will therefore be watched closely, as its success could validate a powerful new approach to developing vaccines against some of the world's most stubborn bacterial infections.